RXi, Philips Ink Research Pact
Worcester-based RXi Pharmaceuticals Corp. and Royal Philips Electronics will work together to find a better way to deliver RNAi-based drugs to patients.
RXi and Netherlands-based Philips signed a joint research agreement that will allow the companies to use Philips ultrasound technology to deliver and monitor RNAi treatments in cells.
One of the challenges of RNAi-based treatments is finding a way to deliver them to their targets while keeping them fully active, RXi said.
The companies hope to "non-invasively" trigger the delivery of RNAi drugs. With ultrasound technology, RXi may be able to target specific organs and tissues, thereby boosting the efficacy of RNAi treatments.
RNAi seeks to treat diseases by interfering with the genes thought to be responsible for those diseases. The technology was discovered by RXi cofounder and UMass Medical School professor Craig Mello.
WBJ Web Partners
Most Recent
Most Recent
0 Comments